Medarex to Present at the Susquehanna Financial Group Healthcare Conference

Printer friendly version
Medarex to Present at the Susquehanna Financial Group Healthcare Conference
PRINCETON, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that it is scheduled to present at the
Susquehanna Financial Group Second Annual SIGnificant Investment Options in
Healthcare Conference at 3:00 p.m. ET on Wednesday, March 5, 2008, in New
York.  The event will be webcast live and will be available in the Investor
Relations section of the Medarex website at www.medarex.com.  An archived
edition of the presentation will be available following the event.

    About Medarex

    Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize a
broad range of fully human antibody product candidates for itself and its
partners. Over forty of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates currently
in Phase 3 clinical trials or the subject of regulatory applications for
marketing authorization. Medarex is committed to building value by developing
a diverse pipeline of antibody products to address the world's unmet
healthcare needs. For more information about Medarex, visit its website at
www.medarex.com.

    Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of
Medarex, Inc.  All rights are reserved.

SOURCE  Medarex, Inc.
    -0-                             02/28/2008
    /CONTACT:  Laura S. Choi, Investor Relations, +1-609-430-2880, x2216, or
Jean Mantuano, Corporate Communications (media), +1-609-430-2880, x2221, both
of Medarex, Inc./
    /Company News On-Call:  http://www.prnewswire.com/comp/108265.html/
    /Web site:  http://www.medarex.com /
    (MEDX)

CO:  Medarex, Inc.
ST:  New Jersey
IN:  HEA MTC BIO
SU:  TDS

RF-JO
-- NETH109 --
3379 02/28/2008 16:00 EST http://www.prnewswire.com